Hearing News Watch

MONTPELLIER, FRANCE — Cilcare announced it will present clinical results from its first observational clinical study, DIAMANT, at the 2026 ARO MidWinter Meeting in Puerto Rico. The results will be presented by Professor Jérôme Nevoux, ENT physician at Bicêtre Hospital, Paris, during a scientific session dedicated to Neural Mechanisms of Speech Perception. Cilcare said sensorineural hearing loss is an underrecognized

The European Union of Hearing Aid Acousticians (EUHA) has issued a call for papers for the 70th International Congress of Hearing Care Acousticians, scheduled for October 14–16, 2026, in Hanover, Germany. EUHA described the meeting as a major international event for the hearing care industry, combining a scientific lecture program with an industry exhibition and networking opportunities. Submission deadline and

INNSBRUCK, AUSTRIA — MED-EL founders Ingeborg and Erwin Hochmair have been named Laureates of the 2026 Queen Elizabeth Prize for Engineering (QEPrize), an international award recognizing engineering innovations with global impact. The 2026 prize highlights the design and development of modern neural interfaces—technologies intended to restore lost human functions—and recognizes engineers whose work has helped establish and advance these approaches. The

BOSTON, MASS. — A new real-world analysis of 97 U.S. patients with bothersome tinnitus treated with Lenire, an FDA-approved bimodal neuromodulation device, has been made available on medRxiv, a preprint server for health sciences. The paper, titled “First Real-World Evidence Utilizing the Multidimensional Tinnitus Functional Index to Assess Treatment Impact with Bimodal Neuromodulation,” reports outcomes measured using both the Tinnitus

MindEar, a digital tinnitus support platform, is offering a free one-week trial of its guided “Sound Wellness Challenge” during Tinnitus Awareness Week 2026 (February 2–9). The company says the seven-day program is designed to help participants try evidence-informed strategies that may reduce tinnitus distress, including sound-based tools, attention and stress regulation techniques, and habit-building approaches that support sleep and daytime

A new observational study suggests that individuals with primary subjective tinnitus are significantly more likely to have low levels of 25-hydroxyvitamin D3 compared with individuals without tinnitus, and that deficiency may be associated with greater tinnitus severity and chronicity. The findings, published in Frontiers in Neurology, add to a growing body of evidence linking vitamin D status to inner ear

WASHINGTON, D.C. — U.S. Senators Adam Schiff (D-Calif.), Marsha Blackburn (R-Tenn.), and Chuck Grassley (R-Iowa) have introduced the Veterans Hearing Aid Improvement Act, bipartisan legislation intended to improve access to hearing aids for eligible veterans through the U.S. Department of Veterans Affairs (VA). The proposed bill would authorize a two-year pilot program allowing the VA to evaluate the use of

WASHINGTON, D.C. — The ACI Alliance has announced that Dr. James A. Robinson, 2024 Nobel Laureate in Economic Sciences, will deliver a keynote lecture at CI2026 Chicago, the international cochlear implant conference scheduled to take place in Chicago in May 2026. Dr. Robinson’s keynote, titled “Why Proven Technologies Fail to Spread: Institutions, Incentives, and the Case of Hearing Health,” will

STONY BROOK, NEW YORK— A smartphone-based digital health application designed to assess fall risk has been recognized by the National Institutes of Health’s National Institute on Aging (NIA) as part of its 2025 Start-Up Challenge for technologies that support healthy aging.The app, CatchU®…Before You Fall, was developed by Jeannette R. Mahoney, PhD, a neurology researcher at Stony Brook Medicine. Mahoney

Eli Lilly has signed an agreement valued at up to $1.12 billion with Germany-based Seamless Therapeutics to develop and commercialize gene-editing treatments for hearing loss, according to a Reuters report. The collaboration further expands Lilly’s growing portfolio of genetic and molecular approaches targeting inherited forms of sensorineural hearing loss. Under the agreement, Lilly will gain access to Seamless Therapeutics’ proprietary